KZA 0.00% 62.0¢ kazia therapeutics limited

Novogen - Cardiovascular Drug Progress report

  1. 5,769 Posts.
    NOVOGEN LIMITED 2002-05-29 ASX-SIGNAL-G

    HOMEX - Sydney

    +++++++++++++++++++++++++
    Australian pharmaceutical company, Novogen Limited, has commenced the
    human clinical trialling phase of its NV-04 cardiovascular drug
    program. The Phase I clinical trial in human volunteers is being
    conducted at the Baker Medical Research institute in Melbourne.

    The objective is to evaluate the safety and tolerability of the
    Novogen drug and to determine its effect on widening of blood vessels
    (dilatation) which is a mechanism of enhancing blood flow and
    reducing blood pressure.

    The purpose of the trial in healthy subjects is to confirm favourable
    results obtained in animals in which improved dilatation of blood
    vessels has been demonstrated with the drug.

    Reduced dilatation of arteries is part of the disease process in
    patients with heart disease, high blood pressure, high blood
    cholesterol and diabetes.

    In separate animal research projects undertaken by the Melbourne
    research team at the Baker Medical Research Institute it has been
    shown previously that NV-04 and closely related compounds from the
    Novogen library promote blood vessel relaxation, lower blood
    pressure, act as antioxidants and inhibit smooth muscle cell growth
    in blood vessels, factors contributing to build up of obstructive
    vascular plaques or atherosclerosis.

    Novogen's Research Director, Professor Alan Husband, said "Not only
    have laboratory studies demonstrated that the synthetic derivative
    NV-04 was effective, but its derivation from naturally occurring
    compounds meant it was expected to be sufficiently safe to be
    administered over long periods without side effects.

    "The commercial potential for the NV-04 program is significant with
    an estimated US$17.7 billion spent annually on cardiovascular drugs
    in the United States alone," Prof Husband said,

    -in view of the anticipated low side effect profile of this class of
    compounds, we expect to have a share of this growing market."

    The NV-04 program has been assisted by an award of $3.75m through
    the Australian Government's R&D START Program.

    For further
    Information: Professor Alan Husband, Research Director, Novogen Ltd
    Mr Christopher Naughton, Managing Director, Novogen Ltd.
    Tel (02) 9878 0088 http://novogen.com
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Last
62.0¢
Change
0.000(0.00%)
Mkt cap ! $44.74M
Open High Low Value Volume
63.5¢ 64.0¢ 61.0¢ $65.55K 104.6K

Buyers (Bids)

No. Vol. Price($)
3 27317 62.0¢
 

Sellers (Offers)

Price($) Vol. No.
65.0¢ 5598 1
View Market Depth
Last trade - 16.10pm 20/01/2020 (20 minute delay) ?
(live)
Last
63.5¢
  Change
0.000 ( 0.79 %)
Open High Low Volume
62.0¢ 63.5¢ 61.0¢ 16234
Last updated 15.42pm 20/01/2020 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.